Literature DB >> 8904427

Determination of stability of Brucella abortus RB51 by use of genomic fingerprint, oxidative metabolism, and colonial morphology and differentiation of strain RB51 from B. abortus isolates from bison and elk.

A E Jensen1, D R Ewalt, N F Cheville, C O Thoen, J B Payeur.   

Abstract

Brucella abortus RB51 and isolates from cattle, bison, and elk were characterized by pulsed-field gel electrophoresis and standard techniques for biotyping Brucella species, which included biochemical, morphological, and antigenic techniques, phage susceptibility, and antibiotic resistance. The objectives were to ascertain the stability of RB51 and to differentiate RB51 from other brucellae. Genomic restriction endonuclease patterns produced by pulsed-field gel electrophoresis demonstrated a unique fingerprint for RB51 relative to other brucellae. Comparisons of the oxidative metabolic profiles of RB51 after time in vivo (14 weeks) and in vitro (75 passages) showed no change in characteristic patterns of oxygen uptake on selected amino acid and carbohydrate substrates. Strain RB51 was biotyped as a typical rough B. abortus biovar 1 (not strain 19) after animal passage or a high number of passages in vitro and remained resistant to rifampin or penicillin and susceptible to tetracycline. No reactions with A or M antiserum or with a monoclonal antibody to the O antigen of Brucella lipopolysaccharides were detected; however, RB51 agglutinated with R antiserum. The results indicate that the genomic fingerprint and rough colonial morphology of RB51 are stable characteristics and can be used to differentiate this vaccine strain from Brucella isolates from cattle, bison, and elk.

Entities:  

Mesh:

Year:  1996        PMID: 8904427      PMCID: PMC228859          DOI: 10.1128/jcm.34.3.628-633.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Differentiation of smooth and nonsmooth colonies of Brucellae.

Authors:  P G WHITE; J B WILSON
Journal:  J Bacteriol       Date:  1951-02       Impact factor: 3.490

2.  Determination of the in vitro sensitivity of Brucella strains to rifampicin.

Authors:  M J Corbel
Journal:  Br Vet J       Date:  1976 May-Jun

3.  Drug susceptibility of Brucella canis isolated from dogs.

Authors:  N Terakado; H Ueda; H Sugawara; Y Isayama; N Koyama
Journal:  Nihon Juigaku Zasshi       Date:  1978-06

4.  Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis.

Authors:  D C Schwartz; C R Cantor
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

5.  Biological properties of RB51; a stable rough strain of Brucella abortus.

Authors:  G G Schurig; R M Roop; T Bagchi; S Boyle; D Buhrman; N Sriranganathan
Journal:  Vet Microbiol       Date:  1991-07       Impact factor: 3.293

6.  Metabolic characterization of the genus Brucella. I. Statistical evaluation of the oxidative rates by which type I of each species can be identified.

Authors:  M E MEYER; H S CAMERON
Journal:  J Bacteriol       Date:  1961-09       Impact factor: 3.490

7.  Characterization of Brucella abortus strain 19 isolated from human and bovine tissues and fluids.

Authors:  M E Meyer
Journal:  Am J Vet Res       Date:  1985-04       Impact factor: 1.156

8.  The existing and potential importance of brucellosis and tuberculosis in canadian wildlife: a review.

Authors:  S V Tessaro
Journal:  Can Vet J       Date:  1986-03       Impact factor: 1.008

9.  Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen.

Authors:  M Phillips; B L Deyoe; P C Canning
Journal:  Am J Vet Res       Date:  1989-12       Impact factor: 1.156

10.  Comparative analysis of immune responses in cattle vaccinated with Brucella abortus strain 19 or strain RB51.

Authors:  M G Stevens; S C Olsen; N F Cheville
Journal:  Vet Immunol Immunopathol       Date:  1995-02       Impact factor: 2.046

View more
  7 in total

1.  Effect of vaccination with Brucella abortus strain RB51 on heifers and pregnant cattle.

Authors:  F A Uza; L Samartino; G Schurig; A Carrasco; K Nielsen; R F Cabrera; H R Taddeo
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

2.  Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation.

Authors:  R Vemulapalli; Y He; L S Buccolo; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses.

Authors:  R Vemulapalli; Y He; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains.

Authors:  R Vemulapalli; J R McQuiston; G G Schurig; N Sriranganathan; S M Halling; S M Boyle
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

5.  Characterization of genomic island 3 and genetic variability of Chilean field strains of Brucella abortus.

Authors:  Sandra Céspedes; Paulina Salgado; Patricio Valenzuela; Roberto Vidal; Angel A Oñate
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

6.  Differential phenotyping of Brucella species using a newly developed semi-automated metabolic system.

Authors:  Sascha Al Dahouk; Holger C Scholz; Herbert Tomaso; Peter Bahn; Cornelia Göllner; Wolfram Karges; Bernd Appel; Andreas Hensel; Heinrich Neubauer; Karsten Nöckler
Journal:  BMC Microbiol       Date:  2010-10-23       Impact factor: 3.605

7.  Defensin susceptibility and colonization in the mouse model of AJ100, a polymyxin B-resistant, Brucella abortus RB51 isolate.

Authors:  Shirley M Halling; Allen E Jensen; Steven C Olsen
Journal:  Curr Microbiol       Date:  2008-01-23       Impact factor: 2.188

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.